KR900700618A - 인터루킨-1억제제 - Google Patents

인터루킨-1억제제

Info

Publication number
KR900700618A
KR900700618A KR1019890702466A KR890702466A KR900700618A KR 900700618 A KR900700618 A KR 900700618A KR 1019890702466 A KR1019890702466 A KR 1019890702466A KR 890702466 A KR890702466 A KR 890702466A KR 900700618 A KR900700618 A KR 900700618A
Authority
KR
South Korea
Prior art keywords
interleukin
inhibitor
dna
sequence
dna sequence
Prior art date
Application number
KR1019890702466A
Other languages
English (en)
Other versions
KR0148009B1 (ko
Inventor
에이취. 하논 챨스
피. 아이젠버그 스티븐
씨. 톰슨 로버트
피. 아렌드 윌리암
지. 조슬린 페니크
소머 안드레아스
Original Assignee
원본미기재
씨네겐 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 씨네겐 인코포레이티드 filed Critical 원본미기재
Priority to KR1019960703435A priority Critical patent/KR970002917B1/ko
Priority claimed from PCT/US1989/002275 external-priority patent/WO1989011540A1/en
Publication of KR900700618A publication Critical patent/KR900700618A/ko
Application granted granted Critical
Publication of KR0148009B1 publication Critical patent/KR0148009B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

인터루킨-1억제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1a도와 제1b도는 2개의 대사적으로-표지시킨 단구 부유물을 Mono Q 크로마토그라피하여 단백질 프로필을 도시한 것이다. 이 세포들은 IgC(제1a도) 또는 태아송아지혈청(제1b도)이 도포된 플레이트에서 배양시킨 것이다.
제2a도는 제1b도에서 지적된 부분의 각 분획들을 전개시킨 겔을 은-염색하여 나타낸 것이다.
제2b도는 제2a도에서 나타낸 겔의 방사선사진이다.
제3a도 및 제3b도 및 제3c도는 실시예 1에서 얻어진 정제된 IL-li에 대한 자료로서, 제3a도는 2중 방사선 패턴을 갖는 크로마 토그라피 자료이고, 제3b도는 제3a도에서 지적된 분획의 시료를 전개시킨 겔을 은-염색하여 나타낸 것이며, 제3c도는 제3b도에 나타낸 겔의 방사선 사진이다.

Claims (25)

  1. 인터루킨-1α 및 인터루킨-1β 중에서 선택된 적어도 하나 이상의 물질에 대해 활성을 갖는 실질적으로 정제된 인터루킨-1 억제제.
  2. 제1항에 있어서의 인터루킨-1 억제제는 포유동물세포에서 유도된 것임을 특징으로 하는 인터루킨-1억제제.
  3. 제1항에 있어서의 인터루킨-1 억제제는 단구로부터 분리된 것임을 특징으로 하는 인터루킨-1억제제.
  4. 제3항에 있어서의 인터루킨-1 억제제는 인간단구로부터 분리된 것임을 특징으로 하는 인터루킨-1억제제.
  5. 제1항에 있어서의 인터루킨-1 억제제는 재조합-DNA 방법에 의해 생산된 것임을 특징으로 하는 인터루킨-1 억제제.
  6. 인터루킨-1 억제제를 제조하는데 있어서, (가) 인터루킨-1 억제 활성을 갖는 단백질을 생산하도록 숙주세포를 조종할 수 있는 DNA시퀀스를 준비한 후, (나) 상기 DNA 시퀀스를 그 DNA시퀀스를 발현시키는데 필요한 작동요소가 포함되어있고 숙주세포로 전이되어 복제될 수 있는 벡터에 클로닝시키고, (다) 상기 합성 DNA시퀀스와 작동요소가 포함되어 있는 벡터를 인터루킨-1 억제제를 코드화하고 있는 DNA를 발현시킬 수 있는 숙주세포로 전이시킨 다음, (라) 상기 숙주세포를 벡터를 증폭시키고 억제제를 발현시키기에 적당한 조건하에서 배양하고, (마) 상기 억제제를 수확하여, (바) 상기 억제제가 활성적인 3차구를 취하도록 하며 인터루킨-1 억제활성을 갖도록 한 것임을 특징으로 하는 DNA-재조합 방법에 의한 인터루킨-1 억제제의 제조방법.
  7. 제7항에 있어서, 상기 DNA 시퀀스는 상보 DNA인 것임을 특징으로 하는 인터루킨-1 억제제의 제조방법.
  8. 제6항에 있어서, 상기 DNA 시퀀스는 제놈 폴리뉴클레오티드 시퀀스인 것임을 특징으로 하는 인터루킨-1 억제제의 제조방법.
  9. 제6항에 있어서, 상기 DNA 시퀀스는 포유동물등을 세포로부터 유도된 것임을 특징으로 하는 인터루킨-1 억제제의 제조방법.
  10. 제9항에 있어서, 상기 DNA 시퀀스는 인간 단구 세포로부터 유도된 것임을 특징으로 하는 인터루킨-1 억제제의 제조방법.
  11. 제6항에 있어서, 상기 숙주 세포는 미생물인 것임을 특징으로 하는 인터루킨-1 억제제의 제조방법.
  12. 제11항에 있어서, 상기 미생물은 E. coli인 것임을 특징으로 하는 인터루킨-1 억제제의 제조방법.
  13. 제6항에 있어서, 상기 숙주세포는 포유동물 세포인 것임을 특징으로 하는 인터루킨-1 억제제의 제조방법.
  14. 제13항에 있어서, 상기 포유동물 세포는 CHO세포인 것임을 특징으로 하는 인터루킨-1 억제제의 제조방법.
  15. 제6항에 있어서, 상기 DNA 시퀀스는 상보 DNA 뉴클레오티드 시퀀스인 것임을 특징으로 하는 인터루킨-1 억제제의 제조방법.
  16. 제6항에 있어서, 상기 DNA 시퀀스는 제놈 뉴클레오티드 시퀀스인 것임을 특징으로 하는 인터루킨-1 억제제의 제조방법.
  17. 인터루킨-1 억제제와 충분히 반복적인 아미노산 시퀀스를 함유하는 적어도 하나이상의 인터루킨-1 억제제의 활성을 갖도록 되어진 폴리펩타이드를 코드화하고 있는 DNA 시퀀스로 이루어진 것임을 특징으로 하는 생리학적 기능을 갖는 인터루킨-1 억제제를 코드화 하고 있는 분리된 DNA 시퀀스.
  18. 제17항에 있어서의 분리된 DNA 시퀀스는 그 DNA 염기 시퀀스가 다음 시퀀스의 99위치와 557위치 사이의 핵산들을 함유하는 것임을 특징으로 하는 분리된 DNA 시퀀스.
  19. 재조합. DNA 분자 GT10-ILIi-2A(ATCC 49488).
  20. 인터루킨-1 억제제 X와 인터루킨-1 억제제 α 및 인터루킨-1β 중 적어도 하나 이상으로 이루어진 것임을 특징으로 하는 실질적으로 정제된 인터루킨-1 억제제.
  21. 제20항에 있어서의 인터루킨-1 억제제는 인터루킨-1 억제제 X인 것임을 특징으로 하는 인터루킨-1 억제제.
  22. 제20항에 있어서의 인터루킨-1 억제제는 인터루킨-1 억제제 α 인 것임을 특징으로 하는 인터루킨-1 억제제.
  23. 제20항에 있어서의 인터루킨-1 억제제는 인터루킨-1 억제제 β인 것임을 특징으로 하는 인터루킨-1 억제제.
  24. 제17항에 있어서의 분리된 DNA 시퀀스는 그 DNA 염기 시퀀스.
  25. 다음의 시퀀스를 갖는 실질적으로 정제된 인터루킨-1 억제제.
    여기서, X는 시스테인, 세린 또는 알라닌이며, Z는 아르기닌 또는 프톨린이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890702466A 1988-05-27 1989-05-25 인터루킨-1 억제제 KR0148009B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019960703435A KR970002917B1 (ko) 1988-05-27 1989-05-25 인터루킨-i 억제제

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US19991588A 1988-05-27 1988-05-27
US199,915 1988-05-27
US23871388A 1988-08-31 1988-08-31
US238,713 1988-08-31
US24852188A 1988-09-23 1988-09-23
US248,521 1988-09-23
US26653188A 1988-11-03 1988-11-03
US266,531 1988-11-13
PCT/US1989/002275 WO1989011540A1 (en) 1988-05-27 1989-05-25 Interleukin-1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019960703435A Division KR970002917B1 (ko) 1988-05-27 1989-05-25 인터루킨-i 억제제

Publications (2)

Publication Number Publication Date
KR900700618A true KR900700618A (ko) 1990-08-16
KR0148009B1 KR0148009B1 (ko) 1998-08-01

Family

ID=27498356

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890702466A KR0148009B1 (ko) 1988-05-27 1989-05-25 인터루킨-1 억제제

Country Status (14)

Country Link
EP (3) EP0541920B1 (ko)
KR (1) KR0148009B1 (ko)
AT (2) ATE88502T1 (ko)
CA (1) CA1341322C (ko)
DE (4) DE68929387T2 (ko)
ES (2) ES2176181T3 (ko)
GR (1) GR900300115T1 (ko)
HK (2) HK1017821A1 (ko)
IE (1) IE66712B1 (ko)
IL (1) IL90423A (ko)
LU (1) LU90943I2 (ko)
NL (1) NL300091I2 (ko)
NZ (1) NZ229326A (ko)
SG (1) SG59969A1 (ko)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
HUT64582A (en) * 1989-11-29 1994-01-28 Synergen Inc Method for producing recombinant human interleukin-1 inhibitor
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
JPH05506986A (ja) * 1990-05-01 1993-10-14 カイロン　コーポレイション インターロイキン―１拮抗物質及びその利用
DK0639079T3 (da) * 1992-04-30 2000-06-13 Amgen Inc Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme
US5981713A (en) * 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5837495A (en) * 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
IT1270662B (it) * 1994-10-13 1997-05-07 Applied Research Systems Antagonista della interleuchina-1
NZ310561A (en) * 1995-09-13 1999-07-29 Takeda Chemical Industries Ltd Immunosuppressant of the aromatic variety based upon the quinoline family
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
CA2287254A1 (en) * 1997-04-21 1998-10-29 Schering Corporation Mammalian cytokines; related reagents and methods
US7205381B2 (en) 1997-04-21 2007-04-17 Schering Corporation Mammalian cytokines; related reagents and methods
US6294655B1 (en) 1998-04-03 2001-09-25 Hyseq, Inc. Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
CA2326066A1 (en) 1998-04-03 1999-10-14 Hyseq, Inc. A interleukin-1 receptor antagonist and uses thereof
US6426191B1 (en) 1998-04-03 2002-07-30 Hyseq, Inc. Assays involving an IL-1 receptor antagonist
US6680380B1 (en) 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
AU6296899A (en) * 1998-10-08 2000-04-26 Zymogenetics Inc. Interleukin-1 homolog
EP1240197A1 (en) * 1999-12-10 2002-09-18 Amgen Inc., Interleukin-1 receptor antagonist-like molecules and uses thereof
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
EP1851245B1 (en) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US10105441B2 (en) 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
DE202009017772U1 (de) 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
KR102080704B1 (ko) 2010-07-29 2020-02-24 세센 바이오, 아이엔씨. 키메라 il-1 수용체 유형 i 항진제 및 길항제들
WO2012076194A1 (de) 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit cytokin-antagonist und corticosteroid
WO2012076193A1 (de) 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit exosomen und corticosteroid
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
UY37651A (es) 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2220662A (en) * 1987-08-26 1990-01-17 Biogen Inc Biological materials,processes for producing biological materials and for using such materials in therapy

Also Published As

Publication number Publication date
EP1133995A2 (en) 2001-09-19
DE10299011I1 (de) 2002-07-18
NL300091I2 (nl) 2002-08-01
GR900300115T1 (en) 1991-09-27
IE66712B1 (en) 1996-01-24
HK1039901A1 (zh) 2002-05-17
DE68906077D1 (de) 1993-05-27
EP0343684A1 (en) 1989-11-29
ES2018750A4 (es) 1991-05-16
IL90423A0 (en) 1990-01-18
SG59969A1 (en) 1999-02-22
LU90943I2 (fr) 2002-09-30
ES2018750T3 (es) 1994-10-16
CA1341322C (en) 2001-11-27
DE68906077T2 (de) 1993-07-29
NL300091I1 (nl) 2002-07-01
HK1017821A1 (en) 1999-11-26
DE10299011I2 (de) 2006-03-16
EP0541920B1 (en) 2002-04-10
DE68929387D1 (de) 2002-05-16
DE343684T1 (de) 1990-11-08
EP0541920A1 (en) 1993-05-19
KR0148009B1 (ko) 1998-08-01
DE68929387T2 (de) 2002-08-14
ATE215966T1 (de) 2002-04-15
IE950317L (en) 1989-11-27
NZ229326A (en) 1992-12-23
EP1133995A3 (en) 2001-09-26
ES2176181T3 (es) 2002-12-01
IE891781L (en) 1989-11-27
IL90423A (en) 2000-07-26
EP0343684B1 (en) 1993-04-21
ATE88502T1 (de) 1993-05-15

Similar Documents

Publication Publication Date Title
KR900700618A (ko) 인터루킨-1억제제
Balhorn et al. Histone phosphorylation and DNA synthesis are linked in synchronous cultures of HTC cells
Fogel et al. Chemical basis for heterogeneity of ribosomal proteins.
KR910015309A (ko) 종양괴사인자(tnf) 억제제 및 그 제조방법
DK639689D0 (da) Indfoering af dna i celler
ATE169956T1 (de) Dna, die für proteine kodiert, die menschliches il-1 binden
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
JPS5970620A (ja) 均質なヒトインタ−ロイキン２及びその製造方法
LU90408I2 (fr) Regranex-becaplermin
DK478786A (da) Cystein-forarmede muteiner af biologisk aktive humantumornekrosefaktorproteiner
ES2064355T3 (es) Procedimiento para cultivar celulas recombinantes.
KR910020033A (ko) 과립구 자극인자(g-csf)의 돌연변이체
ATE208816T1 (de) Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5
DE68925869D1 (de) Modifizierte Proteine, modifizierte Interferone alpha- und beta-phosphorylierte Proteine, DNA-Sequenzen und Analoge und deren Verwendung
ES2074046T5 (es) Procedimiento de construccion de una linea celular animal para la preparacion de beta-interferon humano.
PT84089B (pt) Sequencias de adn codificando para proteinas possuindo a actividade biologica dos inibidores de husi-tipo i, processos biotecnologicos para a preparacao das referidas proteinas e de composicoes farmaceuticas contendo as referidas proteinas
DE3583634D1 (de) Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens.
KR860002526A (ko) 단백질의 상호 분리 방법
ATE208815T1 (de) Genetisches igfbp-5 rodierendes material
Saha et al. Protein synthesis in yeast. Isolation of variant forms of elongation factor 1 from the yeast Saccharomyces cerevisiae.
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
ATE48142T1 (de) Blutprotein, verfahren zu seiner herstellung, antikoerper gegen dieses protein und dieses protein oder diese antikoerper enthaltende pharmazeutische zubereitungen.
Huybrechts-Godin et al. Partial characterization of the macrophage factor that stimulates fibroblasts to produce collagenase and to degrade collagen
Piatigorsky Subunit composition of delta-crystallin from embryonic chick lens. Analysis of methionine-containing tryptic peptides and cyanogen bromide peptides.
DK0414151T3 (da) Humane nervevæskstfaktorproteiner og fremstilling deraf

Legal Events

Date Code Title Description
AMND Amendment
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

E902 Notification of reason for refusal
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120503

Year of fee payment: 15

EXPY Expiration of term